Cantel Medical (Cantel Medical) Risk Assessment

View and export this data going back to 1992. Start your Free Trial

What is Cantel Medical Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Cantel Medical is: No Data: Cannot be evaluated.

Competitive Comparison of Cantel Medical's Risk Assessment

For the Medical Instruments & Supplies subindustry, Cantel Medical's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cantel Medical's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cantel Medical's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Cantel Medical's Risk Assessment falls into.

Cantel Medical (NYSE:CMD) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Cantel Medical Risk Assessment Related Terms

Thank you for viewing the detailed overview of Cantel Medical's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Cantel Medical (Cantel Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cantel Medical Corp (NYSE:CMD) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 Clove Road, 9th Floor, Little Falls, NJ, USA, 07424

Website

http://www.cantelmedical.com

Cantel Medical is a New Jersey-based manufacturer of hospital supplies for infection prevention, which include products used in endoscope disinfection, water purification systems for use in dialysis treatment, and dental supplies. The firm reports in four segments: medical (46% of fiscal 2020 sales), dental (32%), life sciences (19%), and dialysis (3%). Geographic exposure is primarily in the U.S., which accounts for about 75% of revenue, with international markets making up the remaining 25%.

Executives

Ann E Berman	director	255 STATE STREET, BOSTON MA 02109
Jeffrey Z Mann	officer: SVP, General Counsel	150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
George L Fotiades	director, officer: Chief Executive Officer	281 SUMMIT AVENUE, SUMMIT NJ 07901
Charles M Diker	director, 10 percent owner, officer: Chairman	ONE NEW YORK PLAZA, NEW YORK NY 10004
Shaun M. Blakeman	officer: SVP - CFO	C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Jean Casner	officer: SVP and CHRO	150 CLOVE ROAD, LITTLE FALLS NJ 07424
Brian Capone	officer: SVP and Princ. Accounting Ofr	150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Peter G Clifford	officer: President and COO	40 TOURNAMENT DRIVE SOUTH, HAWTHORN WOODS IL 60047
Seth M Yellin	officer: Executive Vice President	150 CLOVE ROAD 9TH FLOOR LITTLE FALLS NJ 07424
Laura L Forese	director	849 STONEWALL COURT FRANKLIN LAKES NJ 07417
Peter Pronovost	director	JHU-QSRG 1909 THAMES ST. - 2ND FLOOR BALTIMORE MD 21231
Anthony B Evnin	director	C/O VENROCK ASSOCIATES, 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Ronnie Myers	director	TOURO COLLEGE OF DENTAL MEDICINE 40 SUNSHINE COTTAGE ROAD VALHALLA NY 10595
Alan R Batkin	director	399 PARK AVENUE, 10TH FLOOR, NEW YORK NY 10022
Karen Prange	director	1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316